Shares of Zoetis, whose pipeline includes medicines and vaccines for pets and livestock, were up 2 percent at $56.65 in extended trading. The company, spun off from Pfizer Inc (PFE.N) in 2013, was valued at $24.85 billion as of Thursday’s close, according to Thomson Reuters data. Both Valeant and Zoetis spokesperson declined to comment.